Antimicrobial Resistance Trends in Escherichia coli, Klebsiella pneumoniae, and Staphylococcus aureus: A Multinational WHO GLASS Analysis

Authors

  • Shehzad Khalil Institute of Biotechnology and Genetic Engineering, The University of Agriculture Peshawar Author
  • Mustafeez Bashar Institute of Biotechnology and Genetic Engineering, The University of Agriculture Peshawar, Pakistan Author
  • Sania Zehra Department of Biotechnology, School of Life Sciences, BRAC University, Dhaka, Bangladesh Author
  • Farheen Tariq Institute of Biotechnology and Genetic Engineers, University of Sindh, Pakistan Author
  • Gulwareena Yousafzai University of Malakand, Khyber Pakhtunkhwa, Pakistan Author

DOI:

https://doi.org/10.61919/w1v79n33

Keywords:

antimicrobial resistance; WHO GLASS; surveillance; multilevel models; overdispersion; reporting completeness; Escherichia coli; Klebsiella pneumoniae; Staphylococcus aureus.

Abstract

Background. Antimicrobial resistance (AMR) is a leading global health threat, and the WHO Global Antimicrobial Resistance and Use Surveillance System (GLASS) is the principal mechanism for multinational AMR surveillance. Countries participate voluntarily and report differing pathogen-antibiotic combinations in different years, so the reported data form an unbalanced panel whose composition changes over time. Objectives. To describe and quantify trends in reported resistance for Escherichia coli, Klebsiella pneumoniae and Staphylococcus aureus using GLASS country-reported data (2018–2023), and to determine how far those trends depend on which countries reported in each year. Methods. Retrospective ecological secondary analysis of WHO XMART country-reported GLASS AMR indicators for 2018–2023. The original extraction on 17 October 2026 was reproduced using a new retrieval on 31 October 2026. Eight clinically prioritised pathogen–antibiotic–specimen combinations were evaluated using binomial mixed-effects models with country-level and observation-level random intercepts. Balanced-panel, inclusion-threshold, country-exclusion and model-specification sensitivity analyses were undertaken, together with Holm adjustment across the eight primary temporal tests and exploratory overdispersion-aware regional analyses. Results. The eight sentinel combinations comprised 2,294 country–year strata from 65 reporting countries and 17,132,532 interpretable antimicrobial susceptibility test (AST) results; the broader descriptive subset contained 8,824 strata from 66 countries. Three combinations showed increasing reported resistance after accounting for extra-binomial heterogeneity and Holm adjustment: K. pneumoniae meropenem (annual OR 1.1453; 95% CI 1.1060–1.1861; adjusted P = 2.34 × 10⁻¹³), E. coli meropenem (OR 1.1860; 95% CI 1.1226–1.2529; adjusted P = 8.14 × 10⁻⁹), and K. pneumoniae ciprofloxacin (OR 1.0684; 95% CI 1.0430–1.0946; adjusted P = 4.58 × 10⁻⁷). All three retained direction and significance across seven alternative scenarios. The other five combinations had no statistically significant primary temporal association. Exploratory overdispersion-aware regional interaction tests were significant in three combinations. For E. coli ciprofloxacin resistance in blood, the all-reporter pooled change was −1.8 percentage points and the balanced-panel change was +7.4 percentage points, yielding a descriptive participation contrast of −9.2 percentage points. Conclusions. Among reporting countries, reported meropenem resistance in E. coli and K. pneumoniae and ciprofloxacin resistance in K. pneumoniae increased between 2018 and 2023. These associations were robust to sensitivity and multiplicity analyses, but they do not establish national population-level resistance trends or treatment outcomes. Changes in reporting-country composition materially affected crude comparisons, highlighting the need to report denominator, participation and model uncertainty when interpreting multinational surveillance data. 

References

1. Murray CJL, Ikuta KS, Sharara F, Swetschinski L, Robles Aguilar G, Gray A, et al. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022;399(10325):629-655. doi:10.1016/S0140-6736(21)02724-0.

2. Naghavi M, Vollset SE, Ikuta KS, Swetschinski LR, Gray AP, Wool EE, et al. Global burden of bacterial antimicrobial resistance 1990–2021: a systematic analysis with forecasts to 2050. Lancet. 2024;404(10459):1199-1226. doi:10.1016/S0140-6736(24)01867-1.

3. Sartorius B, Gray AP, Davis Weaver N, Robles Aguilar G, Swetschinski LR, Ikuta KS, et al. The burden of bacterial antimicrobial resistance in the WHO African region in 2019: a cross-country systematic analysis. Lancet Glob Health. 2024;12(2):e201-e216. doi:10.1016/S2214-109X(23)00539-9.

4. Mestrovic T, Naghavi M, Robles Aguilar G, Davis Weaver N, Swetschinski LR, Wool EE, et al. The burden of bacterial antimicrobial resistance in the WHO Eastern Mediterranean Region 1990–2021: a cross-country systematic analysis with forecasts to 2050. Lancet Public Health. 2025;10(11):e955-e970. doi:10.1016/S2468-2667(25)00201-4.

5. Pitout JD, Laupland KB. Extended-spectrum β-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis. 2008;8(3):159-166. doi:10.1016/S1473-3099(08)70041-0.

6. Nordmann P, Naas T, Poirel L. Global Spread of Carbapenemase-producing Enterobacteriaceae. Emerg Infect Dis. 2011;17(10):1791-1798. doi:10.3201/eid1710.110655.

7. Bezabih YM, Sabiiti W, Alamneh E, Bezabih A, Peterson GM, Bezabhe WM, et al. The global prevalence and trend of human intestinal carriage of ESBL-producing Escherichia coli in the community. J Antimicrob Chemother. 2021;76(1):22-29. doi:10.1093/jac/dkaa399.

8. Navon-Venezia S, Kondratyeva K, Carattoli A. Klebsiella Pneumoniae: A Major Worldwide Source and Shuttle for Antibiotic Resistance. FEMS Microbiol Rev. 2017;41(3):252–75. doi:10.1093/femsre/fux013.

9. World Health Organization. WHO Bacterial Priority Pathogens List, 2024: Bacterial Pathogens of Public Health Importance to Guide Research, Development and Strategies to Prevent and Control Antimicrobial Resistance [Internet]. 2024 [cited 2026 Nov 9]. Available from: https://www.who.int/publications/i/item/9789240093461.

10. Lee AS, de Lencastre H, Garau J, Kluytmans J, Malhotra-Kumar S, Peschel A, et al. Methicillin-resistant Staphylococcus aureus. Nat Rev Dis Primers. 2018;4(1):18033. doi:10.1038/nrdp.2018.33.

11. Turner NA, Sharma-Kuinkel BK, Maskarinec SA, et al. Methicillin-Resistant Staphylococcus Aureus: An Overview of Basic and Clinical Research. Nat Rev Microbiol. 2019;17(4):203–18. doi:10.1038/s41579-018-0147-4.

12. World Health Organization. GLASS Report: Early Implementation 2016–2017 [Internet]. 2017 [cited 2026 Nov 9]. Available from: https://www.who.int/publications/i/item/9789241513449.

13. World Health Organization. GLASS Manual for Antimicrobial Resistance Surveillance in Common Bacteria Causing Human Infection [Internet]. 2023 [cited 2026 Nov 9]. Available from: https://iris.who.int/handle/10665/372741.

14. World Health Organization. Global Antibiotic Resistance Surveillance Report 2025 [Internet]. 2025 [cited 2026 Nov 9]. Available from: https://www.who.int/publications/i/item/9789240116337.

15. Tornimbene B, Eremin S, Abednego R, Abualas EO, Boutiba I, Egwuenu A, et al. Global Antimicrobial Resistance and Use Surveillance System on the African continent: Early implementation 2017–2019. Afr J Lab Med. 2022;11(1):1594. doi:10.4102/ajlm.v11i1.1594.

16. Iskandar K, Molinier L, Hallit S, Sartelli M, Hardcastle TC, Haque M, et al. Surveillance of antimicrobial resistance in low- and middle-income countries: a scattered picture. Antimicrob Resist Infect Control. 2021;10(1):63. doi:10.1186/s13756-021-00931-w.

17. Gandra S, Alvarez-Uria G, Turner P, Joshi J, Limmathurotsakul D, van Doorn HR. Antimicrobial Resistance Surveillance in Low- and Middle-Income Countries: Progress and Challenges in Eight South Asian and Southeast Asian Countries. Clin Microbiol Rev. 2020;33(3):e00048-19. doi:10.1128/CMR.00048-19.

18. Do PC, Assefa YA, Batikawai SM, Reid SA. Strengthening antimicrobial resistance surveillance systems: a scoping review. BMC Infect Dis. 2023;23(1):593. doi:10.1186/s12879-023-08585-2.

19. Gahimbare L, Muvunyi CM, Guessennd NAK, Rutanga JP, Gashema P, Fuller W, et al. Antimicrobial Resistance in the WHO African Region: A Systematic Literature Review 2016–2020. Antibiotics. 2024;13(7):659. doi:10.3390/antibiotics13070659.

20. Pezzani MD, Tornimbene B, Pessoa-Silva C, de Kraker M, Rizzardo S, Salerno ND, et al. Methodological quality of studies evaluating the burden of drug-resistant infections in humans due to the WHO Global Antimicrobial Resistance Surveillance System target bacteria. Clin Microbiol Infect. 2021;27(5):687-696. doi:10.1016/j.cmi.2021.01.004.

21. Al-Haboubi M, Glover RE, Eastmure E, Petticrew M, Black N, Mays N. Quality and Utility of Information Captured by Surveillance Systems Relevant to Antimicrobial Resistance (AMR): A Systematic Review. Antibiotics. 2021;10(4):431. doi:10.3390/antibiotics10040431.

22. de Kraker MEA, Lipsitch M. Burden of Antimicrobial Resistance: Compared to What?. Epidemiol Rev. 2021;43(1):53-64. doi:10.1093/epirev/mxab001.

23. Robinson WS. Ecological Correlations and the Behavior of Individuals. Am Sociol Rev. 1950;15(3):351–357. doi:10.2307/2087176.

24. Hinde J, Demétrio CGB. Overdispersion: Models and estimation. Comput Stat Data Anal. 1998;27(2):151-170. doi:10.1016/S0167-9473(98)00007-3.

25. Bolker BM, Brooks ME, Clark CJ, et al. Generalized Linear Mixed Models: A Practical Guide for Ecology and Evolution. Trends Ecol Evol. 2009;24(3):127–35. doi:10.1016/j.tree.2008.10.008.

26. World Health Organization. GLASS-2025: Analysis Code Supporting the WHO GLASS 2025 Report [Internet]. 2026 [cited 2026 Nov 9]. Available from: https://github.com/GlobalAMR/GLASS-2025.

27. Ajulo S, Awosile B. Global antimicrobial resistance and use surveillance system (GLASS 2022): Investigating the relationship between antimicrobial resistance and antimicrobial consumption data across the participating countries. PLoS One. 2024;19(2):e0297921. doi:10.1371/journal.pone.0297921.

28. Khalid L, Saleem K, Mushtaq S, Hussain I, Hussain Z, Hussain Z, et al. Global prediction of antimicrobial resistance trends using statistical and machine learning models: Evaluating national action plan policy impacts through interrupted time series analysis. J Glob Antimicrob Resist. 2026;46:214-226. doi:10.1016/j.jgar.2025.11.022.

29. Alvarez-Uria G, Gandra S, Mandal S, Laxminarayan R. Global forecast of antimicrobial resistance in invasive isolates of Escherichia coli and Klebsiella pneumoniae. Int J Infect Dis. 2018;68:50-53. doi:10.1016/j.ijid.2018.01.011.

30. Waterlow NR, Cooper BS, Robotham JV, Knight GM. Antimicrobial resistance prevalence in bloodstream infection in 29 European countries by age and sex: An observational study. PLoS Med. 2024;21(3):e1004301. doi:10.1371/journal.pmed.1004301.

31. Waterlow NR, Chandler CIR, Cooper BS, Moore CE, Robotham JV, Sartorius B, et al. Combining demographic shifts with age-based resistance prevalence to estimate future antimicrobial resistance burden in Europe and implications for targets: A modelling study. PLoS Med. 2025;22(11):e1004579. doi:10.1371/journal.pmed.1004579.

32. Chitumba HO, Ramos N. Antimicrobial resistance data gaps in sub-Saharan Africa: The case of Angola in the Global Antibiotic Resistance Surveillance Report 2025. J Glob Antimicrob Resist. 2026;50:64-65. doi:10.1016/j.jgar.2026.05.008.

33. von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for Reporting Observational Studies. PLoS Med. 2007;4(10):e296. doi:10.1371/journal.pmed.0040296.

34. Vandenbroucke JP, von Elm E, Altman DG, Gøtzsche PC, Mulrow CD, Pocock SJ, et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): Explanation and Elaboration. PLoS Med. 2007;4(10):e297. doi:10.1371/journal.pmed.0040297.

35. World Health Organization. XMART Public Data API: Use of the API [Internet]. 2026 [cited 2026 Nov 9]. Available from: https://extranet.who.int/xmart4/docs/xmart_api/use_API.html.

36. World Health Organization. GLASS Dashboard: Global AMR and AMU Interactive Profiles [Internet]. 2025 [cited 2026 Nov 9]. Available from: https://worldhealthorg.shinyapps.io/glass-dashboard/.

37. World Health Organization and Epi-interactive. GLASS Dashboard Source Code [Internet]. 2025 [cited 2026 Nov 9]. Available from: https://github.com/WorldHealthOrganization/GLASS-Dashboard.

38. Bates D, Mächler M, Bolker B, Walker S. Fitting Linear Mixed-Effects Models Using lme4. J Stat Softw. 2015;67(1):1–48. doi:10.18637/jss.v067.i01.

39. R Core Team. R: a language and environment for statistical computing [Internet]. R Foundation for Statistical Computing; 2026 [cited 2026 Nov 9]. Available from: https://www.R-project.org/.

40. Wickham H, Averick M, Bryan J, Chang W, McGowan L, François R, et al. Welcome to the Tidyverse. J Open Source Softw. 2019;4(43):1686. doi:10.21105/joss.01686.

41. Pebesma E. Simple Features for R: Standardized Support for Spatial Vector Data. R J. 2018;10(1):439–46. doi:10.32614/RJ-2018-009.

42. Kourtis AP, Hatfield K, Baggs J, Mu Y, See I, Epson E, et al. Vital Signs: Epidemiology and Recent Trends in Methicillin-Resistant and in Methicillin-Susceptible Staphylococcus aureus Bloodstream Infections — United States. MMWR Morb Mortal Wkly Rep. 2019;68(9):214-219. doi:10.15585/mmwr.mm6809e1.

Downloads

Published

2026-11-15

How to Cite

[1]
Khalil, S. et al. 2026. Antimicrobial Resistance Trends in Escherichia coli, Klebsiella pneumoniae, and Staphylococcus aureus: A Multinational WHO GLASS Analysis. Link Medical Journal. 4, 2 (Nov. 2026), e272. DOI:https://doi.org/10.61919/w1v79n33.